Clinical Trials

Find trials

Perform a New Search

Search Results 41-50 of 76 for soft tissue sarcoma

Edit search filters

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Open for enrollment	View complete study & contact information

Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

See Details

Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

Location:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.

About this study

The purpose of this study is to provide patients who have locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST) and have received treatment with at least 2 prior Food and Drug Administration (FDA)-approved therapies early access to ripretinib until such time that ripretinib becomes commercially available or the Sponsor chooses to discontinue the program.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla.	Closed for enrollment	View complete study & contact information
Rochester, Minn.	Closed for enrollment
Scottsdale/Phoenix, Ariz.	Closed for enrollment

Print study details

Site IRB:
- Jacksonville, Florida: 19-011101
- Rochester, Minnesota: 19-011101
- Scottsdale/Phoenix, Arizona: 19-011101
NCT ID:
NCT04148092
Sponsor Protocol Number:
DCC-2618-99-001

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients with Gastrointestinal Stromal Tumour After Progression with Imatinib

Jacksonville, FL, Rochester, MN
- See Details
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients with Gastrointestinal Stromal Tumour After Progression with Imatinib
- Location:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  3
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Closed for enrollment
View complete study & contact information

Rochester, Minn.

Closed for enrollment

Print study details
Site IRB:
Jacksonville, Florida: 12-003940
Rochester, Minnesota: 12-003940

NCT ID:
NCT01694277

Sponsor Protocol Number:
AB11002

A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib

Location:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
3
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to compare the effectiveness of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 358 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Closed for enrollment	View complete study & contact information
Scottsdale/Phoenix, Ariz.	Closed for enrollment
Jacksonville, Fla.	Closed for enrollment

Print study details

Site IRB:
- Rochester, Minnesota: 18-009703
- Scottsdale/Phoenix, Arizona: 18-009703
- Jacksonville, Florida: 18-009703
NCT ID:
NCT03673501
Sponsor Protocol Number:
DCC-2618-03-002

A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors

Location:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
1
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to characterize the safety and tolerability of single agent HFB301001 and to determine recommended dose expansino (RDE(s) and a recommended Phase 2 dose (RP2D).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla.	Open for enrollment	View complete study & contact information
Rochester, Minn.	Open for enrollment
Scottsdale/Phoenix, Ariz.	Open for enrollment

Print study details

Site IRB:
- Jacksonville, Florida: 21-009057
- Rochester, Minnesota: 21-009057
- Scottsdale/Phoenix, Arizona: 21-009057
NCT ID:
NCT05229601
Sponsor Protocol Number:
HFB-301001-01

Pagination Clinical studies

Clinical Trials

Filter Results

Locations

Study status

Gender

Age

Study phase

Search Results 41-50 of 76 for soft tissue sarcoma

A Study of Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumors that are Recurrent or Cannot Be Removed by Surgery

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

A Study of Unesbulin Combined with Dacarbazine to Treat Advanced Leiomyosarcoma (LMS)

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

An Early Access Program (EAP) for Avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor

Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients with Gastrointestinal Stromal Tumour After Progression with Imatinib

A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib

A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions